RENGEN-COV
This week the FDA approved RENGEN-COV under an emergency use authorization. The treatment works by attaching monoclonal antibodies to the novel coronavirus when it first enters the body and preventing it from invading new cells and replicating. This treatment is for adults and children over age 12 exposed to SARS-CoV-2 who might be at high risk of developing severe COVID-19. Individuals considered at high risk include those who are not fully vaccinated, those who are immunocompromised, and those who reside in nursing homes. The person does not need to have a diagnosis of Covid to receive this treatment, but just be exposed to it. Typically, a person receives monoclonal antibodies though an IV; however, the FDA has approved a subcutaneous injection to deliver the treatment.
If you are supporting someone who may be high risk, you may want to consider contacting their physician and discussing this treatment for them. Lastly, RENGEN-COV is not to be used as a substitute for the Covid Vaccines.